Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
Neurology|December 1, 2012
Orexin receptor antagonism for treatment of insomnia: a randomized clinical trial of suvorexantW Joseph Herring, Ellen Snyder, Kerry Budd, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|January 17, 2020
Polysomnographic assessment of suvorexant in patients with probable Alzheimer's disease dementia and insomnia: a randomized trialW Joseph Herring, Paulette Ceesay, Ellen Snyder, et al.
Sleep Medicine|August 8, 2013
Alertness and psychomotor performance effects of the histamine-3 inverse agonist MK-0249 in obstructive sleep apnea patients on continuous positive airway pressure therapy with excessive daytime sleepiness: a randomized adaptive crossover studyW Joseph Herring, Kenneth Liu, Jill Hutzelmann, et al.
The International Journal of Neuropsychopharmacology|March 17, 2016
A Phase II Dose-Ranging Study Evaluating the Efficacy and Safety of the Orexin Receptor Antagonist Filorexant (MK-6096) in Patients with Primary InsomniaKathryn M Connor, Erin Mahoney, Saheeda Jackson, et al.
Sleep|June 4, 2008
Slow wave sleep enhancement with gaboxadol reduces daytime sleepiness during sleep restrictionJames K Walsh, Ellen Snyder, Janine Hall, et al.
Lancet Regional Health. Americas|November 18, 2024
Opportunities for tuberculosis elimination in the Canadian Arctic: cost-effectiveness of community-wide screening in a remote Arctic communityAlice Zwerling, Edwina Veerasingam, Ellen Snyder, et al.
Journal of Sleep Research|August 2, 2021
Pilot evaluation of a consumer wearable device to assess sleep in a clinical polysomnography trial of suvorexant for treating insomnia in patients with Alzheimer's diseaseVladimir Svetnik, Ting-Chuan Wang, Paulette Ceesay, et al.
Plos One|January 17, 2020
The effectiveness of substance use interventions for homeless and vulnerably housed persons: A systematic review of systematic reviews on supervised consumption facilities, managed alcohol programs, and pharmacological agents for opioid use disorderOlivia Magwood, Ginetta Salvalaggio, Michaela Beder, et al.
The Lancet. Neurology|April 1, 2014
Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: a phase 3 randomised, double-blind, placebo-controlled trialDavid Michelson, Ellen Snyder, Erin Paradis, et al.
Psychopharmacology|March 8, 2017
Clinical profile of suvorexant for the treatment of insomnia over 3 months in women and men: subgroup analysis of pooled phase-3 dataW Joseph Herring, Kathryn M Connor, Ellen Snyder, et al.
Pageof 3